Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zmax · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Zmax | DRUG | - |
Inclusion Criteria: * Have clinical signs/symptoms of AOM in at least 1 ear Exclusion Criteria: * Known or suspected hypersensitivity, or intolerance to azithromycin or other macrolides or to any penicillin, beta-lactam antibiotic or beta lactamase inhibitor * Previously diagnosed disease(s) of i...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Smith & Nephew plc Sponsored ADR | SNN | 1 | PHASE4 | Iontophoresis and tube placement |
| Merck & Co., Inc. | MRK | 1 | PHASE4 | Undisclosed |
Zmax is an investigational small molecule being developed for the treatment of otitis media, an infection or inflammation of the middle ear. It is being studied in a pediatric population, with clinical trials focusing on acute otitis media.
Zmax is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research to evaluate the drug's safety and efficacy in treating otitis media.
Zmax is in Phase 3 clinical development. It has completed one Phase 3 trial, which was a randomized, double-blind study. The drug is still investigational and has not been approved by regulatory authorities for commercial use.
Zmax has been studied in one completed Phase 3 clinical trial with the identifier NCT00360100. This trial, titled 'Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media,' enrolled 120 participants and was conducted in the United States, Argentina, Chile, Costa Rica, Dominican Republic, Guatemala, and Panama.
Zmax is not FDA approved. It is an investigational drug that has completed a Phase 3 clinical trial for otitis media, but it remains in clinical development and has not received marketing approval from the U.S. Food and Drug Administration or any other regulatory agency.
Yes, Zmax is being studied in a pediatric population. The completed Phase 3 clinical trial enrolled participants as young as 3 months old, with no upper age limit specified, and included both male and female participants. The study focused on treating acute otitis media in this age group.